SRR1348339
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.337
- OXIDATIVE_PHOSPHORYLATION+0.301
- PANCREAS_BETA_CELLS+0.268
- SPERMATOGENESIS+0.258
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.207
- MYOGENESIS+0.198
- APICAL_SURFACE+0.116
- ESTROGEN_RESPONSE_LATE+0.069
- APICAL_JUNCTION+0.060
- KRAS_SIGNALING_UP+0.054
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.462
- G2M_CHECKPOINT-0.404
- E2F_TARGETS-0.395
- TNFA_SIGNALING_VIA_NFKB-0.391
- NOTCH_SIGNALING-0.366
- INTERFERON_GAMMA_RESPONSE-0.353
- UNFOLDED_PROTEIN_RESPONSE-0.353
- MYC_TARGETS_V2-0.350
- INTERFERON_ALPHA_RESPONSE-0.331
- DNA_REPAIR-0.325
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR817797 | GTEX | — | 0.941 |
| 2 | SRR819134 | GTEX | — | 0.939 |
| 3 | SRR1414897 | GTEX | — | 0.929 |
| 4 | SRR1474509 | GTEX | — | 0.926 |
| 5 | SRR1413625 | GTEX | — | 0.925 |
| 6 | SRR1453851 | GTEX | — | 0.925 |
| 7 | SRR1480059 | GTEX | — | 0.923 |
| 8 | SRR1341763 | GTEX | — | 0.919 |
| 9 | SRR1418923 | GTEX | — | 0.918 |
| 10 | SRR1458134 | GTEX | — | 0.918 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.337 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.301 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.268 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.258 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.207 | Inavolisib | — uncovered |
| MYOGENESIS | 0.198 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.116 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.069 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.060 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.054 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.043 | Inavolisib | — uncovered |